Join us for an informative discussion on living with multiple myeloma! We’ve partnered with @Patient Power to provide a FREE, online talk with patient advocates & myeloma experts on everything from the latest treatment options to managing side effects.

Corporate Match

An easy way to double your contribution is through employee giving programs. Many corporations match employee donations to our organization. CLICK BELOW to see if your employer will match your donation!

When you shop at, Amazon donates.

Precision Myeloma Initiative

By combining analysis of big data technologies, genetics, and patient medical and treatment history, Precision Myeloma empowers doctors to give personalized care leading to longer survival, better treatment tolerability, and ultimately a cure.

Donate and help us develop this exciting new project!



Join us as we celebrate Rob, Sidney, Richard, and John Living Their Best Life. Learn how you can help IMBCR continue to make the impossible possible to extend the lives of myeloma patients.

previous arrow
next arrow

At IMBCR, we have boldly set out to reimagine therapeutic approaches and patient monitoring strategies for multiple myeloma.

We focus on the individual needs of patients, not just treatment, but all-encompassing care.  Collaborating with centers of excellence and industry leaders globally, we explore available drugs, novel agents, and new targets.  These efforts will help to determine optimal and personalized treatments to maximize their benefits for each patient.  IMBCR’s published research provides the gateway to transformative therapies resulting in superior outcomes.  This has resulted in patients receiving advanced precision care and extending their life expectancy.

Patients with multiple myeloma want to know their physician is giving them the best care possible.

Patients are focused on:



IMBCR research enables clinicians to identify the disease faster, optimize treatment plans, and provide the most effective therapy available.  See how IMBCR Initiatives are accomplishing this.

Learn More

Precision Care
Quality of Life
Living Their Best Life!

Launching 2021

By combining analysis of big data technologies, genetics, and patient medical and treatment history, Precision Myeloma empowers doctors to give personalized care leading to longer survival, better treatment tolerability and ultimately a cure.

Help us develop this exciting new project.

Learn More

Living Life Free of Myeloma

Ultimately our goal is to eradicate myeloma and allow patients to continue to live their best life!

IMBCR future initiative
Cure Myeloma

Learn More

Multiple myeloma is a rare blood cancer of malignant cells found in the bone marrow that has had many therapeutic breakthroughs in the past decade; and, as a result, has become perhaps the most complicated cancer to treat and manage.

You Can Help

The Institute for Myeloma & Bone Cancer Research (IMBCR), formed in 2003, is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.

It is through the support of our donors that IMBCR is able to reimagine drug development strategies for multiple myeloma and determine optimal and personalized combinations to maximize their benefits for patients.

We are dedicated to making the impossible possible so that all patients with myeloma live their best life.

Dr. James R. Berenson, a global innovative thought leader in multiple myeloma, formed the Institute for Myeloma & Bone Cancer Research (IMBCR) in 2003.  This offers scientists the opportunity to work in an unencumbered environment to explore new directions in a state of the art, self-contained laboratory facility. IMBCR is a team of dedicated scientists with extensive expertise in cancer research, particularly in the fields of myeloma, metastatic bone cancer, genetics, immunology, and tumor microenvironment. They use models of myeloma and other bone cancers to make groundbreaking discoveries that have led to many new treatments for these diseases and ways to monitor them.